These are some of the stocks posting the largest moves midday.
— The Danish drugmaker stock added 5.5% after saying late Tuesday it was halting Ozempic's kidney disease treatment trial after a committee said an analysis showed signs of success.— Shares of dialysis services providers DaVita and Fresenius Medical Care sank 18.4% and 19.6%, respectively, on Novo Nordisk's news. Baxter International, which makes products for chronic dialysis therapies, slid 9%.shale rival Pioneer Natural Resources for $59.
Feeling out of the loop? We'll catch you up on the Chicago news you need to know. Sign up for the weekly— Shares slipped 2% after CEO Bruce Broussard said he will step down from his position in the latter half of 2024. The company named Jim Rechtin of ENvision Healthcare as his successor.— The biopharma stock added 3.5% following an upgrade from Leerink to outperform. Analyst David Risinger cited an expanding earnings multiple and pipeline newsflow as catalysts.— Shares gained 6.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Stock movers: Novo Nordisk, Fresenius Medical Care, DaVita, Thor IndustriesNovo Nordisk, Thor Industries, Silk Road Medical, Fresenius Medical Care, and DaVita all showed stock price movement in pre-market trading
Baca lebih lajut »
Stock movers: DaVita, Exxon Mobil, Ozempic drug parent Novo NordiskExxon Mobil stock falls after the oil giant announces a $59.5 billion all-stock deal to buy Pioneer Natural Resources
Baca lebih lajut »
Stocks making the biggest moves premarket: Plug Power, Exxon Mobil, Pioneer, Novo Nordisk and moreThese are the stocks posting the largest moves in premarket trading.
Baca lebih lajut »
Stocks making the biggest moves premarket: Plug Power, Exxon Mobil, Pioneer, Novo Nordisk and moreThese are the stocks posting the largest moves in premarket trading.
Baca lebih lajut »
Novo Nordisk, Eli Lilly leap as Ozempic show promise in kidney patient treatmentOzempic, the diabetes treatment often prescribed for weight loss, is also proving highly-effective in treating patients with chronic kidney disease.
Baca lebih lajut »
Novo Nordisk stops Ozempic kidney trial after early signs of successNovo Nordisk (NOVOb.CO) said on Tuesday it will stop a trial studying Ozempic to treat kidney failure in diabetes patients ahead of schedule because it was clear from an interim analysis that the treatment would succeed.
Baca lebih lajut »